Related Experiment Video
Updated: May 5, 2026
08:19
Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
Published on: November 17, 2015
17.8K
A comprehensive review on alpha-lipoic acid delivery by nanoparticles
Navid Mosallaei1, Amirhossein Malaekeh-Nikouei2, Setayesh Sarraf Shirazi2
1Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Bioimpacts : BI
|November 4, 2024
Summary
Nanoparticulate delivery systems enhance alpha-lipoic acid (ALA) effectiveness by overcoming its low bioavailability and short half-life. These advanced systems offer improved stability and targeted delivery for various health conditions.
Area of Science:
- Pharmacology and Drug Delivery
- Nanotechnology
- Biochemistry
Background:
- Alpha-lipoic acid (ALA) possesses significant antioxidant properties with therapeutic potential for diverse health conditions.
- ALA's clinical utility is limited by poor bioavailability, rapid metabolism, and an undesirable odor.
- Nanoparticulate drug delivery systems offer a promising strategy to mitigate ALA's limitations.
Purpose of the Study:
- To comprehensively review nanoparticulate delivery systems for alpha-lipoic acid (ALA).
- To evaluate various nanoparticulate carriers for enhancing ALA's therapeutic efficacy.
- To highlight advancements in ALA delivery for improved treatment outcomes.
Main Methods:
- Review of literature on nanoparticulate systems for ALA delivery.
- Categorization of carriers including lipid-based nanoparticles, nanoemulsions, polymeric nanoparticles, films, nanofibers, and gold nanoparticles.
- Analysis of advantages such as improved stability, sustained release, and enhanced bioavailability.
Main Results:
- ALA-loaded solid lipid nanoparticles (SLNs) show promise for dermatological applications.
- Niosomes encapsulating ALA demonstrate potential in treating cerebral ischemia.
- Cationic nanoemulsions and chitosan-coated liposomes exhibit advantages for ophthalmic and transdermal delivery, respectively.
Conclusions:
- Nanoparticulate systems effectively address ALA's bioavailability and stability challenges.
- These advanced delivery strategies significantly enhance ALA's therapeutic potential across various medical fields.
- Innovative nanoparticulate approaches pave the way for improved ALA-based therapeutics.
More Related Videos
Related Concept Videos
01:16Bioavailability Enhancement: Drug Solubility Enhancement
499
Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
499
01:27Bioavailability Enhancement: Drug Permeability Enhancement
352
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
352
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
01:30Modified-Release Drug Delivery Systems: Bioavailability
170
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
170
01:24Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160